Genetic trio of BRAF and TERT alterations and rs2853669TT in papillary thyroid cancer aggressiveness

• Published in: JNCI : Journal of the National Cancer Institute 2024-05, Vol.116 (5), p.694-701
• Main Authors: Liu, Rengyun, Zhu, Guangwu, Tan, Jie, Shen, Xiaopei, Xing, Mingzhao
• Format: Article
• Language: English
• Subjects: Adult; Carcinoma, Papillary - genetics; Carcinoma, Papillary - pathology; Female; Genotype; Humans; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local - genetics; Polymorphism, Single Nucleotide; Prognosis; Promoter Regions, Genetic; Proto-Oncogene Proteins B-raf - genetics; Telomerase - genetics; Thyroid Cancer, Papillary - genetics; Thyroid Cancer, Papillary - pathology; Thyroid Neoplasms - genetics; Thyroid Neoplasms - pathology
• ISSN: 0027-8874; 1460-2105
• DOI: 10.1093/jnci/djad265

BRAF V600E and TERT promoter alterations are core components in current genetics-based risk assessment for precision management of papillary thyroid cancer. It remains unknown whether this approach could achieve even better precision through a widely recognized prognostic single-nucleotide variation (SNV, formerly SNP), rs2853669T>C, in the TERT promoter. The genetic status of alterations and SNV were examined by sequencing genomic DNA from papillary thyroid cancer in 608 patients (427 women and 181 men) aged 47 years (interquartile range = 37-57), with a median follow-up time of 75 months (interquartile range = 36-123), and their relationship with clinical outcomes was analyzed. A luciferase reporter assay was performed to examine TERT promoter activities. TERT promoter alterations showed a strong association with papillary thyroid cancer recurrence in the presence of genotype TT of rs2853669 (adjusted hazard ratio [HR] = 2.12, 95% confidence interval [CI] = 1.10 to 4.12) but not TC/CC (adjusted HR = 1.17, 95% CI = 0.56 to 2.41). TERT and BRAF alterations commonly coexisted and synergistically promoted papillary thyroid cancer recurrence. With this genetic duet, TT of rs2853669 showed a robustly higher disease recurrence than TC/CC (adjusted HR = 14.26, 95% CI = 2.86 to 71.25). Patients with the genetic trio of BRAF V600E, TERT alteration, and TT of rs2853669 had a recurrence of 76.5% vs recurrence of 8.4% with neither variation and with TC/CC (HR = 13.48, 95% CI = 6.44 to 28.21). T allele of rs2853669 strongly increased TERT promoter activities, particularly the variant promoters. The SNV rs2853669T>C dramatically refines the prognostic power of BRAF V600E and TERT promoter alterations to a higher precision, suggesting the need for including this SNV in the current genetics-based risk prognostication of papillary thyroid cancer.